Volume 95 Issue 15 | p. 15 | Concentrates
Issue Date: April 10, 2017

Sucampo buys start-up Vtesse

Department: Business
Keywords: rare disease, Vtesse, cyclodextrin, Niemann-Pick Disease

Sucampo Pharmaceuticals will pay $200 million in stock and cash to acquire Vtesse, a privately held firm focused on rare diseases. Launched in January 2015, Vtesse was the first spin-off from the Pfizer-backed orphan drug accelerator Cydan Development. Vtesse’s lead product is VTS-270, a mixture of 2-hydroxypropyl-β-cyclodextrins in Phase II/III trials for the ultrarare genetic disorder Niemann-Pick disease type C1 (NPC). After the acquisition closes, Vtesse’s former owners intend to put a portion of proceeds, to be matched by Sucampo, into a new NPC-related research foundation.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment